Safety and Effectiveness of Taking Choline Supplements During Pregnancy for Improving Infant Brain Development
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00332124 |
Recruitment Status :
Completed
First Posted : June 1, 2006
Last Update Posted : September 2, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pregnancy Child Development | Drug: Choline Dietary Supplement: Placebo | Phase 1 |
Choline is an essential nutrient that can be found in foods, such as egg yolks, liver, and other meats. It is important for the composition and repair of normal cellular membranes, normal brain function, and normal cardiovascular function. Research has suggested that the presence of adequate amounts of choline during pregnancy and breastfeeding can help ensure healthy fetal brain development. Additionally, adequate prenatal choline levels may have long-lasting positive effects on cognitive function, including memory. However, sufficient research has not been done on the effects of choline on pregnant women and their unborn babies. This study will evaluate the safety and effectiveness of taking choline supplements during pregnancy, and whether taking choline during pregnancy will have an effect on infant development.
Participants in this double-blind study will be randomly assigned to receive either placebo or 900 mg of choline daily throughout pregnancy, until delivery. Babies will then begin receiving either placebo or choline daily from the time of birth until they are 3 months old. Participants will attend a baseline study visit that will include eligibility assessment, urine collection, measurement of vital signs, dispensing of study medication, and an ultrasound. Subsequent study visits will occur every 4 weeks throughout pregnancy and 6 months postpartum. Vital signs will be taken, urine samples will be collected, and study medication will be given at each visit. Two blood samples will be taken between Weeks 32 and 36 of gestation. Heel sticks will be performed on babies when they are 4 and 12 weeks old. Follow-up visits will be held every 6 months until the baby is 18 months old.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 351 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Double-blind Trial of Phosphatidylcholine During Pregnancy and Infant Serum Choline Levels |
Actual Study Start Date : | June 2006 |
Actual Primary Completion Date : | March 2017 |
Actual Study Completion Date : | March 2017 |
Arm | Intervention/treatment |
---|---|
Placebo Comparator: 1
Participants will take placebo
|
Dietary Supplement: Placebo
Corn oil every day in place of choline |
Active Comparator: 2
Participants will take choline
|
Drug: Choline
900 mg every day until birth of infant
Other Name: Polyenylphosphatidylcholine |
- Sensory Gaiting (P50) [ Time Frame: Measured at birth, 1 month and 3 months after birth ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 45 Years (Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Pregnant
- Between 10 and 18 weeks gestational age
- Healthy
- Diagnosis of psychosis
Exclusion Criteria:
- Use of any tobacco or nicotine product
- Drinks more than 1 alcoholic drink per day
- Use of illicit drugs
- History of trimethylaminuria
- History of kidney disease
- History of liver disease
- History of pre-pregnancy diabetes
- History of Parkinson's disease
- History of fetal death, fetal/infant congenital malformation, or fetal/infant genetic abnormality
- Evidence of noncompliance to study medication

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00332124
United States, Colorado | |
University of Colorado Denver | |
Aurora, Colorado, United States, 80045 |
Principal Investigator: | Robert Freedman, MD | University of Colorado, School of Medicine, |
Responsible Party: | University of Colorado, Denver |
ClinicalTrials.gov Identifier: | NCT00332124 |
Other Study ID Numbers: |
04-0678 DATR A5-ETPD |
First Posted: | June 1, 2006 Key Record Dates |
Last Update Posted: | September 2, 2020 |
Last Verified: | August 2020 |
Choline Lipotropic Agents Hypolipidemic Agents Antimetabolites |
Molecular Mechanisms of Pharmacological Action Gastrointestinal Agents Lipid Regulating Agents Nootropic Agents |